Nobivac DHP lyophilisate and solvent for suspension for injection for dogs

Authorised

- Canine distemper virus, strain Onderstepoort, Live
- Canine adenovirus 2, strain Manhattan LPV3, Live
- Canine parvovirus, strain 154, Live

Product identification

Medicine name:
Nobivac DHP lyophilisate and solvent for suspension for injection for dogs
Nobivac DHP vet.

Active substance:
Canine distemper virus, strain Onderstepoort, Live

Canine adenovirus 2, strain Manhattan LPV3, Live

Canine parvovirus, strain 154, Live

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Canine distemper virus, strain Onderstepoort, Live
10000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Canine adenovirus 2, strain Manhattan LPV3, Live
10000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Canine parvovirus, strain 154, Live
10000000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Pharmaceutical form:
Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AD02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Norway

Package description:
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 10 single dose vials of diluent.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 50 single dose vials of diluent.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 50 single dose vials of vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 10 single dose vials of

vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 50 single dose vials. The diluent is packed together with the vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 10 single dose vials. The diluent is packed together with the vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 10 single dose vials of diluent.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 50 single dose vials of diluent.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 50 single dose vials of vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 10 single dose vials of vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 50 single dose vials. The diluent is packed together with the vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 10 single dose vials. The diluent is packed together with the vaccine.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
12/10/2005

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
Norwegian Medical Products Agency

Authorisation number:
05-3333

Date of authorisation status change:
12/11/2009

Reference member state:
Ireland

Procedure number:
IE/V/0161/001

Concerned member states:
Netherlands Norway United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 16/01/2026
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

ie-puar-mr-iev0161001-nobivac-dhp-lyophilisate-and-solvent-for-suspensio-en.pdf